TAK-375 Takeda.

Author(s): Cajochen C

Affiliation(s): Centre for Chronobiology, Psychiatric University Clinic, Basel, Switzerland. christian.cajochen@pukbasel.ch

Publication date & source: 2005-01, Curr Opin Investig Drugs., 6(1):114-21.

Publication type: Review

TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.